From Monday 25th November 2024, the NEY GLH will begin to analyse and report a small number of additional clinical trials targets from its solid tumour NGS panels. The details below set out how this will be achieved.

Changes from November 2024

For solid tumour samples received after Monday 25th November 2024, we will commence analysis and reporting of the Step 1 additional clinical trials targets for the majority of solid tumour samples WHERE THEY ARE INCLUDED IN THE PANEL BEING TESTED. This will be for 5 genes associated with the DETERMINE clinical trial (Cancer Clinical Trial | DETERMINE Precision Medicine (cancerresearchuk.org)). These genes are included in the National Genomic Test Directory v10 dated 23rd October 2024, which sets out the targets under 2 new columns entitled “Target Gene(s) Clinical trials” and “Further Eligibility Criteria Clinical trials targets only”.

 

CLICK HERE TO READ MORE ABOUT THESE CHANGES AND FURTHER SUPPORT